GW Pharmaceuticals PLC (GWPH) Earns Buy Rating from Cantor Fitzgerald
GW Pharmaceuticals PLC (NASDAQ:GWPH)‘s stock had its “buy” rating reiterated by stock analysts at Cantor Fitzgerald in a note issued to investors on Monday. They presently have a $208.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 81.23% from the company’s current price.
The analysts wrote, “Tonight (11/20), the American Epilepsy Society (AES) published the abstracts for the upcoming annual meeting in early December.””
GWPH has been the topic of a number of other reports. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $124.00 price target on shares of GW Pharmaceuticals PLC in a report on Friday, October 6th. Zacks Investment Research lowered GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Maxim Group set a $135.00 price target on GW Pharmaceuticals PLC and gave the company a “buy” rating in a report on Monday, August 7th. Evercore ISI assumed coverage on GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They issued an “outperform” rating and a $154.00 price target on the stock. Finally, Leerink Swann restated an “outperform” rating and issued a $153.00 price target (down from $160.00) on shares of GW Pharmaceuticals PLC in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. GW Pharmaceuticals PLC has a consensus rating of “Buy” and a consensus price target of $144.55.
Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down $1.11 during trading on Monday, hitting $114.77. The stock had a trading volume of 414,820 shares, compared to its average volume of 319,576. GW Pharmaceuticals PLC has a 12 month low of $92.65 and a 12 month high of $136.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.26 and a current ratio of 10.39.
Several large investors have recently added to or reduced their stakes in GWPH. Janus Henderson Group PLC acquired a new stake in shares of GW Pharmaceuticals PLC in the second quarter valued at about $70,128,000. Pictet Asset Management Ltd. increased its position in shares of GW Pharmaceuticals PLC by 102.6% in the third quarter. Pictet Asset Management Ltd. now owns 355,263 shares of the biopharmaceutical company’s stock valued at $36,056,000 after acquiring an additional 179,911 shares during the last quarter. Redmile Group LLC increased its position in shares of GW Pharmaceuticals PLC by 33.8% in the second quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock valued at $44,605,000 after acquiring an additional 112,392 shares during the last quarter. Employees Retirement System of Texas acquired a new position in GW Pharmaceuticals PLC during the second quarter worth approximately $5,313,000. Finally, Capital World Investors increased its position in GW Pharmaceuticals PLC by 6.3% during the second quarter. Capital World Investors now owns 675,800 shares of the biopharmaceutical company’s stock worth $67,749,000 after buying an additional 40,000 shares during the last quarter. 75.57% of the stock is currently owned by institutional investors and hedge funds.
GW Pharmaceuticals PLC Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.